Éric Legouffe
Institut de Cancérologie de Bourgogne(FR)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research
Most-Cited Works
- → Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study(2012)709 cited
- → BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone(2003)563 cited
- → Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial(2022)291 cited
- → Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial(2002)264 cited
- → The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature(2005)257 cited
- → Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial(2015)237 cited
- → Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial(2011)236 cited
- → CD200 is a new prognostic factor in multiple myeloma(2006)230 cited
- → Survival and Proliferation Factors of Normal and Malignant Plasma Cells(2003)211 cited
- → Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma(2012)162 cited